Pfizer (NYSE: PFE) has now enrolled 36,576 participants in the late-stage clinical trial of its coronavirus vaccine candidate, BNT162b2, which it's developing with BioNTech (NASDAQ: BNTX) . Last month, the companies increased their planned enrollment in the study from 30,000 to approximately 44,000, meaning that it is currently 83% enrolled.
Pfizer and BioNTech have signed up more participants than Moderna (NASDAQ: MRNA) , which had 28,043 people in the clinical trial of its vaccine candidate, mRNA-1273, as of Friday evening. Moderna's phase 3 trial still has a target of 30,000 participants, so it'll likely reach full enrollment first....Moderna has given its booster shots to 19,369 participants, while 28,146 participants in Pfizer and BioNTech's study have received their second doses. Therefore, it seems likely Pfizer and BioNTech will be able to make an initial data readout first.
www.fool.com/investing/2020/10/05/...rolled-83-of-their-up-s/
AstraZeneca Plc and GlaxoSmithKline Plc
will be the first pharmaceutical companies to be able to utilize the Cambridge-1 Supercomputer by Nvidia "Tackling the world's most pressing challenges in healthcare requires massively powerful computing resources to harness the capabilities of AI," said Jensen Huang, CEO of Nvidia.
www.benzinga.com/general/biotech/20/10/...dge-1-supercomputer